Gufic BioSciences Adjusts Valuation Amid Declining Profits and Market Sentiment
Gufic BioSciences, a small-cap pharmaceutical company, has experienced a recent adjustment in its evaluation, reflecting changes in its financial metrics. Key indicators include a PE ratio of 41.45 and a ROCE of 15.31%. Despite a year-over-year return of 12.27%, the company faces challenges, including a profit decline.
Gufic BioSciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, indicating a notable change in its financial standing. The company's price-to-earnings (PE) ratio stands at 41.45, while its price-to-book value is recorded at 6.38. Additionally, the enterprise value to EBITDA ratio is 25.97, suggesting a premium valuation compared to industry peers. Gufic BioSciences has also reported a return on capital employed (ROCE) of 15.31% and a return on equity (ROE) of 15.40%, highlighting its operational efficiency.
Despite a year-over-year return of 12.27%, the company has faced challenges, including a decline in profits of 2.6%. The recent quarter's performance has shown negative trends, with operating profit to interest ratios at their lowest. Furthermore, the stock's technical indicators have shifted to a bearish outlook, reflecting broader market sentiments.
In light of these developments, Gufic BioSciences' evaluation has been adjusted, emphasizing the need for careful consideration of its financial metrics and market position.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
